Sinead B. Bleiel

Dr. Sinead B. Bleiel

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
SASara Arroyo-Moreno
Sara Arroyo-Moreno
GSGonzalo Saiz-Gonzalo
Gonzalo Saiz-Gonzalo
SMSeamus McSweeney
Seamus McSweeney
SBSinead B. Bleiel
Sinead B. Bleiel
Probiotic enumeration in foods and beverages remains anchored in culture dependent colony-forming unit (CFU) counts, the regulatory gold standard for label compliance. However, culturability does not fully equate to viability as environmental stresses can convert probiotic cells into a viable but non-culturable (VBNC) state, where they remain metabolically active but undetectable by CFU counts. Microencapsulation can provide a degree of protection to probiotics against stress; nevertheless, this blind spot in quantification forces manufacturers to overdose formulations or risk non-compliance with health benefits claims. Thus, the efficacy of probiotics may be underestimated when evaluation relies solely on CFU, creating a false dichotomy between VBNC and non-viable cells. Culture-independent methods, including flow cytometry quantification of active fluorescent units (AFUs), viability PCR/dPCR, and rRNA-targeted Flow-FISH, can aid closing this gap by detecting metabolically active cells non-detectable by culturing, providing complementary quantification data to CFU counts alone. Understanding the relationship between quantification by culture and culture-independent methods provides a more accurate measure of probiotic dose delivery in functional foods and beverages. This review covers the current understanding of VBNC state, including induction, detection, and resuscitation in probiotics, with emphasis on experimental controls that differentiate true VBNC resuscitation from population growth. Case studies in Lactobacillus and Bifidobacterium illustrate triggers, molecular mechanisms, and methodological advances. Finally, guidance is provided for the development of an integrated quantification approach that reconciles culture-dependent and culture-independent data, ultimately aiming to improve CFU count accuracy through the controlled resuscitation of VBNC cells.

17 November 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
AAAnnick Alleleyn
Annick Alleleyn
MAMark Van Avesaat
Mark Van Avesaat
DRDina Ripken
Dina Ripken
SBSinead B. Bleiel
Sinead B. Bleiel
DKDaniel Keszthelyi
Daniel Keszthelyi
AMA.A.M. Masclee
A.A.M. Masclee
Activation of the intestinal brake by infusing nutrients into the distal small intestine with catheters inhibits food intake and enhances satiety. Encapsulation of macronutrients, which protects against digestion in the proximal gastrointestinal tract, can be a non-invasive alternative to activate this brake. In this study, we investigate the effect of oral ingestion of an encapsulated casein and sucrose mixture (active) targeting the distal small intestine versus a control product designed to be released in the stomach on food intake, satiety, and plasma glucose concentrations. Fifty-nine volunteers received the active and control product on two separate test days. Food intake was determined during an ad libitum meal 90 min after ingestion of the test product. Visual analogue scale scores for satiety and blood samples for glucose analysis were collected at regular intervals. Ingestion of the active product decreased food intake compared to the control product (655 kcal compared with 699 kcal, respectively, p < 0.05). The area under the curve (AUC) for hunger was decreased (p < 0.05) and AUC for satiety was increased (p < 0.01) after ingestion of the active product compared to the control product. Ingestion of an encapsulated protein-carbohydrate mixture resulted in inhibition of food intake compared to a non-encapsulated control product.

4 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JHJoanne Heade
Joanne Heade
FMFiona McCartney
Fiona McCartney
MCMiguel Chenlo
Miguel Chenlo
OMOlga Moreno Marro
Olga Moreno Marro
MSMaja Severic
Maja Severic
David BraydenDavid Brayden
David Brayden
For many diabetics, daily, lifelong insulin injections are required to effectively manage blood glucose levels and the complications associated with the disease. This can be a burden and reduces patient quality of life. Our goal was to develop a more convenient oral delivery system that may be suitable for insulin and other peptides. Insulin was entrapped in 1.5-mm beads made from denatured whey protein isolate (dWPI) using gelation. Beads were then air-dried with fumed silica, Aerosil®. The encapsulation efficiency was ~61% and the insulin loading was ~25 µg/mg. Dissolution in simulated gastric-, and simulated intestinal fluids (SGF, SIF) showed that ~50% of the insulin was released from beads in SGF, followed by an additional ~10% release in SIF. The omission of Aerosil® allowed greater insulin release, suggesting that it formed a barrier on the bead surface. Circular dichroism analysis of bead-released insulin revealed an unaltered secondary structure, and insulin bioactivity was retained in HepG2 cells transfected to assess activation of the endogenous insulin receptors. Insulin-entrapped beads were found to provide partial protection against pancreatin for at least 60 min. A prototype bead construct was then synthesised using an encapsulator system and tested in vivo using a rat intestinal instillation bioassay. It was found that 50 IU/kg of entrapped insulin reduced plasma glucose levels by 55% in 60 min, similar to that induced by subcutaneously (s.c.)-administered insulin (1 IU/kg). The instilled insulin-entrapped beads produced a relative bioavailability of 2.2%. In conclusion, when optimised, dWPI-based beads may have potential as an oral peptide delivery system.

1 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JHJoanne Heade
Joanne Heade
RKRobert Kent
Robert Kent
SBSinead B. Bleiel
Sinead B. Bleiel
David BraydenDavid Brayden
David Brayden
The oral route of administration is by far the most convenient route, especially in the treatment of chronic conditions. However, many therapeutics present formulation difficulties which make them unsuitable for oral delivery. Recently, we synthesized a denatured whey protein isolate (dWPI) bead entrapped with insulin. Our present goal was to assess the suitability of this delivery system to the delivery of other potential molecules, both hydrophilic and hydrophobic. Beads of 1.2–1.5 mm in diameter were entrapped with four payloads representing a range of solubilities. The water-soluble payloads were sodium fluorescein (SF) and FITC dextran 4000 Da (FD4), while the hydrophobic ones were Fast Green and curcumin. Encapsulation efficiency (EE) was 73%, 84%, 70%, and 83% for SF, FD4, Fast Green, and curcumin-loaded beads, respectively. The corresponding loading capacity for each bead was 0.07%, 1.1%, 0.75%, and 1.1%, respectively. Each payload produced different release profiles in simulated gastric fluid (SGF) and simulated intestinal fluids (SIF). SF released steadily in both SGF and SIF. FD4 and curcumin release was not substantial in any buffers, while Fast Green release was low in SGF and high in SIF. The differences in release behaviour were likely due to the varying properties of the payloads. The effect of proteolysis on beads suggested that enzymatic degradation of the whey bead may promote payload release. The beads swelled rapidly in SGF compared to SIF, which likely contributed to the release from the beads, which was largely governed by solvent diffusion and polymer relaxation. Our results offer a systematic examination of the behaviour of hydrophilic and hydrophobic payloads in a dWPI delivery system. These beads may be further designed to orally deliver poorly permeable macromolecules and poorly soluble small molecules of pharmaceutical interest.

31 January 2026 in Journal of AOAC INTERNATIONAL
Verified
Journal Article
Closed access
GSGonzalo Saiz-Gonzalo
Gonzalo Saiz-Gonzalo
OOOrlaith O’COnnell
Orlaith O’COnnell
SJShima Joy
Shima Joy
SMSeamus McSweeney
Seamus McSweeney
NKNooshin Vahedi Kia
Nooshin Vahedi Kia
SBSinead B. Bleiel
Sinead B. Bleiel
Background: Accurate probiotic enumeration ensures the dose delivered to the mammalian host. Plate count (PC) detects only culturable cells and can underestimate the total number of viable cells, particularly when some cells are injured or dormant and do not form colonies. Objective: To qualify a flow cytometry assay reporting active fluorescent units (AFU) and to compare counts with the PC method for micro-encapsulated Lacticaseibacillus rhamnosus GG in a snack product. Methods: Following AOAC INTERNATIONAL, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and United States Pharmacopeia (USP) principles, precision, accuracy, ruggedness, specificity, and robustness of plate count and flow cytometry methods were evaluated for the first time in a commercial yogurt-bite snack product. Results: Both methods fulfilled the pre-specified performance targets (RSD ≤15%; AFU recovery 100–104%; live/dead R2 ≥0.95). Analyst-to-analyst differences were not significant. Flow cytometry spike recoveries were 100–104% across targets. Live/dead mixtures tracked linearly (R2 ≥0.95). Across matched samples, AFU and CFU values were equivalent within a pre-specified ±0.5 log band; batch means typically differed by ≤0.2 log with no systematic bias. Conclusion: The qualified flow cytometry method provides same-day counts and enumerates all membrane-intact cells, complementing plate counts while meeting analytical performance criteria. Findings endorse the use of AFU in tandem to CFU assessment for probiotic quantification, label accuracy and estimation of microbiome-relevant dose in snack and finished-product matrixes. Highlights: Flow cytometry provided same-day results and enumerated all membrane-intact cells for label verification in snack matrixes.

8 July 2026 in SLEEP Advances
Verified
Journal Article
Open access
GSGonzalo Saiz-Gonzalo
Gonzalo Saiz-Gonzalo
AAAhmed W. Al-Humadi
Ahmed W. Al-Humadi
SMSeamus McSweeney
Seamus McSweeney
Carel W. Le RouxCarel W. Le Roux
Carel W. Le Roux
SBSinead B. Bleiel
Sinead B. Bleiel
Sleep restriction, serotonin biology, and gut-brain signaling are interconnected, but whether habitual short sleep is associated with altered peripheral serotonin in healthy adults remains unclear. Probiotic modulation of circulating serotonin has also been insufficiently characterized. In this exploratory randomized, double-blind, placebo-controlled study, 21 healthy adults received microencapsulated Lacticaseibacillus rhamnosus GG or placebo for 28 days and were classified by habitual sleep duration as short sleepers (≤5 h/night) or adequate sleepers (≥6 h/night). Fasting serum serotonin was measured at baseline and day 28. Habitual short sleep was not associated with elevated serum serotonin. Female sex was associated with higher adjusted day-28 serum 5-HT in the primary winsorized log-transformed ANCOVA model (Type II ANOVA: F = 6.04, p = .03, partial η2 = 0.29), whereas treatment and sleep group did not show evidence of association. Although no statistically detectable independent probiotic effect was identified in this small exploratory sample. Directional decreases were observed in some participants with higher baseline serotonin values. These findings suggest that sex may be an important source of variation in peripheral serotonin and support further adequately powered studies using objective sleep phenotyping and prespecified sex-stratified analyses.